159 related articles for article (PubMed ID: 25433814)
1. Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma.
Fernández-Vega I; Quirós LM; Santos-Juanes J; Pane-Foix M; Marafioti T
Virchows Arch; 2015 Feb; 466(2):229-35. PubMed ID: 25433814
[TBL] [Abstract][Full Text] [Related]
2. Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas.
Miles RR; Mankey CC; Seiler CE; Smith LB; Teruya-Feldstein J; Hsi ED; Elenitoba-Johnson KS; Lim MS
Hum Pathol; 2009 Dec; 40(12):1731-7. PubMed ID: 19716163
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase A is highly expressed in classical Hodgkin lymphoma.
Li PC; Siddiqi IN; Mottok A; Loo EY; Wu CH; Cozen W; Steidl C; Shih JC
J Pathol; 2017 Oct; 243(2):220-229. PubMed ID: 28722111
[TBL] [Abstract][Full Text] [Related]
4. Bruton's tyrosine kinase inhibitors: lessons learned from bench-to-bedside (first) studies.
Ysebaert L; Michallet AS
Curr Opin Oncol; 2014 Sep; 26(5):463-8. PubMed ID: 25033375
[TBL] [Abstract][Full Text] [Related]
5. Clusterin expression in malignant lymphomas: a survey of 266 cases.
Saffer H; Wahed A; Rassidakis GZ; Medeiros LJ
Mod Pathol; 2002 Nov; 15(11):1221-6. PubMed ID: 12429802
[TBL] [Abstract][Full Text] [Related]
6. Focal adhesion kinase (FAK) expression in normal and neoplastic lymphoid tissues.
Ozkal S; Paterson JC; Tedoldi S; Hansmann ML; Kargi A; Manek S; Mason DY; Marafioti T
Pathol Res Pract; 2009; 205(11):781-8. PubMed ID: 19647948
[TBL] [Abstract][Full Text] [Related]
7. Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
Seiler T; Dreyling M
Expert Opin Investig Drugs; 2017 Aug; 26(8):909-915. PubMed ID: 28661188
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of STAT6
Van Slambrouck C; Huh J; Suh C; Song JY; Menon MP; Sohani AR; Duffield AS; Goldberg RC; Dama P; Kiyotani K; Godfrey J; Fitzpatrick C; Kline J; Smith SM; Jaffe ES; Hartmann S; Venkataraman G
Mod Pathol; 2020 May; 33(5):834-845. PubMed ID: 31822802
[TBL] [Abstract][Full Text] [Related]
9. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker.
Torlakovic E; Torlakovic G; Nguyen PL; Brunning RD; Delabie J
Am J Surg Pathol; 2002 Oct; 26(10):1343-50. PubMed ID: 12360049
[TBL] [Abstract][Full Text] [Related]
10. Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
Uckun FM; Qazi S
Expert Opin Ther Pat; 2010 Nov; 20(11):1457-70. PubMed ID: 20831363
[TBL] [Abstract][Full Text] [Related]
11. Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas.
Krenács D; Borbényi Z; Bedekovics J; Méhes G; Bagdi E; Krenács L
Virchows Arch; 2015 Sep; 467(3):345-55. PubMed ID: 26089142
[TBL] [Abstract][Full Text] [Related]
12. Expression of Bruton's tyrosine kinase in B-cell neoplasms evaluated by flow cytometry.
Marcondes NA; Fernandes FB; Alegretti AP; Faulhaber GAM
Clin Exp Med; 2017 Nov; 17(4):499-504. PubMed ID: 28028621
[TBL] [Abstract][Full Text] [Related]
13. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.
Smith CI; Baskin B; Humire-Greiff P; Zhou JN; Olsson PG; Maniar HS; Kjellén P; Lambris JD; Christensson B; Hammarström L
J Immunol; 1994 Jan; 152(2):557-65. PubMed ID: 8283037
[TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase prevents activation of the anti-apoptotic transcription factor STAT3 and promotes apoptosis in neoplastic B-cells and B-cell precursors exposed to oxidative stress.
Uckun F; Ozer Z; Vassilev A
Br J Haematol; 2007 Feb; 136(4):574-89. PubMed ID: 17367410
[TBL] [Abstract][Full Text] [Related]
15. Utilization of monoclonal antibody L26 in the identification and confirmation of B-cell lymphomas. A sensitive and specific marker applicable to formalin-and B5-fixed, paraffin-embedded tissues.
Cartun RW; Coles FB; Pastuszak WT
Am J Pathol; 1987 Dec; 129(3):415-21. PubMed ID: 3322020
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical studies of protein kinase D (PKD) 2 expression in malignant human lymphomas.
Kovalevska LM; Yurchenko OV; Shlapatska LM; Berdova GG; Mikhalap SV; Van Lint J; Sidorenko SP
Exp Oncol; 2006 Sep; 28(3):225-30. PubMed ID: 17080017
[TBL] [Abstract][Full Text] [Related]
17. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
MacPartlin M; Smith AM; Druker BJ; Honigberg LA; Deininger MW
Leukemia; 2008 Jul; 22(7):1354-60. PubMed ID: 18548107
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of the human MIXL1 gene product in non-Hodgkin and Hodgkin lymphomas.
Drakos E; Rassidakis GZ; Leventaki V; Guo W; Medeiros LJ; Nagarajan L
Hum Pathol; 2007 Mar; 38(3):500-7. PubMed ID: 17303500
[TBL] [Abstract][Full Text] [Related]
19. Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis.
Churchill HR; Roncador G; Warnke RA; Natkunam Y
Hum Pathol; 2010 Dec; 41(12):1726-34. PubMed ID: 20825974
[TBL] [Abstract][Full Text] [Related]
20. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
Miettinen M
Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
